Cell Free Tumor DNA to Monitor Response to Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Non-Small Cell Lung Cancer

被引：0
|
作者：
Ulivi, Paola [1 ]
Chiadini, Elisa [1 ]
Marisi, Giorgia [1 ]
Ludovini, Vienna [2 ]
De Luigi, Nicoletta [3 ]
Dazzi, Claudio [4 ]
Mariotti, Marita [3 ]
Crino, Lucio [2 ]
Delmonte, Angelo [3 ]
机构：
[1] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Biosci Lab, Meldola, Italy
[2] Azienda Osped Perugia, Santa Maria Misericordia Hosp, Med Oncol, Perugia, Italy
[3] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Med Oncol, Meldola, Italy
[4] S Maria Croci Hosp, Med Oncol, Ravenna, Italy
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
EGFR T790M; free DNA; TKI; Resistance;
D O I：
10.1016/j.jtho.2016.11.1702
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.02b035
引用
收藏
页码：S1208 / S1208
页数：1
相关论文
共 50 条
  • [41] Vitamin D enhances erlotinib response in EGFR-mutant non-small cell lung cancer
    Shaurova, Tatiana
    Shoemaker, Suzanne F.
    Hershberger, Pamela A.
    CANCER RESEARCH, 2016, 76
  • [42] Osimertinib in EGFR-mutant non-small cell lung carcinoma
    Lorenz, Judith
    PNEUMOLOGIE, 2023, 77 (11): : 847 - 847
  • [43] The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors
    Lee, Ji Yun
    Ku, Bo Mi
    Lim, Sung Hee
    Lee, Min-Young
    Kim, Haesu
    Kim, Moonjin
    Kim, Sungmin
    Jung, Hyun Ae
    Sun, Jong-Mu
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (06) : 903 - 909
  • [44] Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer?
    Roviello, Giandomenico
    Zanotti, Laura
    Cappelletti, Maria Rosa
    Gobbi, Angela
    Dester, Martina
    Paganini, Giovanni
    Pacifico, Chiara
    Generali, Daniele
    Roudi, Raheleh
    CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 18 (01) : 15 - 20
  • [45] Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer?
    Giandomenico Roviello
    Laura Zanotti
    Maria Rosa Cappelletti
    Angela Gobbi
    Martina Dester
    Giovanni Paganini
    Chiara Pacifico
    Daniele Generali
    Raheleh Roudi
    Clinical and Experimental Medicine, 2018, 18 : 15 - 20
  • [46] Management of EGFR-Mutant Non-Small Cell Lung Cancer: Focus on Gefitinib
    Naito, Yoichi
    Goto, Koichi
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 1027 - 1040
  • [47] ctDNA for the Evaluation and Management of EGFR-Mutant Non-Small Cell Lung Cancer
    Desai, Aakash
    Vazquez, Tadana A.
    Arce, Keishla M.
    Corassa, Marcelo
    Mack, Philip C.
    Gray, Jhanelle E.
    Pellini, Bruna
    CANCERS, 2024, 16 (05)
  • [48] Tackling Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer
    Blaquier, Juan Bautista
    Ortiz-Cuaran, Sandra
    Ricciuti, Biagio
    Mezquita, Laura
    Cardona, Andres Felipe
    Recondo, Gonzalo
    CLINICAL CANCER RESEARCH, 2023, 29 (18) : 3579 - 3591
  • [49] Patritumab Deruxtecan Is Efficacious in EGFR-Mutant Non-Small Cell Lung Cancer
    Zhang, H.
    Yu, X.
    Ye, J.
    Li, H.
    Hu, J.
    Tan, Y.
    CANCER DISCOVERY, 2023, 13 (12) : 2501 - 2501
  • [50] Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: A new era begins
    Remon, J.
    Moran, T.
    Majem, M.
    Reguart, N.
    Dalmau, E.
    Marquez-Medina, D.
    Lianes, P.
    CANCER TREATMENT REVIEWS, 2014, 40 (01) : 93 - 101
12345